Activity Summary:
Talking Hemophilia A is a roundtable discussion continuing education activity designed to inform and guide on integrating novel therapies into hemophilia A treatment paradigms.

The expert faculty presenters will provide an overview of existing approaches and their limitations and how new and emerging therapies can be used to address unmet needs. The activity will be supported by downloadable, supplemental slides that have the key discussion and teaching points.

Activity Summary:
Lightning Reports are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. These activities are designed to keep healthcare professionals on top of the most recent clinical findings.

This series of accredited continuing education enduring videos will provide brief commentary spotlighting hot topics in myelodysplastic syndromes (MDS) presented at the 2022 American Society for Hematology (ASH) Annual Meeting from New Orleans, Louisiana.

Activity Summary:
The Talking Post-Transplant Acute Myeloid Leukemia (AML) webcast series will provide recent updates to improve outcomes in post-transplantation relapse in AML.

This webcast series, led by expert faculty, will provide guidance and practical strategies to safely implement recent progress in addressing post-transplantation relapse in AML. Through patient cases and scenarios, faculty presenters will guide the integration of new evidence into clinical treatment paradigms of AML in the post-transplantation setting. The activity will be supported by downloadable slides that have the key discussion/teaching points.

*Healthcare providers may only claim for the participation of one (1) enduring archive activity.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

Patients with PH-ILD face a dismal prognosis and are associated with reduced exercise capacity, greater need for supplemental oxygen, and a decreased quality of life. In recent years, there have been several advances in the treatment and management of PH-ILD. This slide kit will use three case scenarios to illustrate best-practice approaches to accurately diagnose PH-ILD and differentiate it from group 1 pulmonary arterial hypertension (PAH). It will also provide guidance on integrating recent progress in the treatment of PH-ILD and on the safe and effective use of approved and emerging therapy.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to bruising and bleeding. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins (IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP. Since 2008, the approval of thrombopoietin-receptor agonists (TPO-RAs) including a second-generation oral TPO-RA and a spleen tyrosine kinase (Syk) inhibitor, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment. This landscape will be further transformed with a sizable clinical pipeline including inhibitors of CD20, CD40, neonatal Fc receptor (FcRn), bruton’s tyrosine kinase (BTK), and Syk signaling.

This slide kit is designed to keep busy clinicians abreast of the emerging evidence for available treatments and the novel therapy pipeline, to optimize the treatment and care for patients with ITP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Clinical Viewpoints Hereditary Angioedema lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slides developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Hereditary angioedema (HAE) is a potentially life-threatening genetic condition that presents many unique challenges. The diagnosis of HAE is based on suggestive clinical history and physical findings. In addition, optimal management relies on a patient-centered and shared decision-making approach despite the recent significant advances in treatment options. This activity uses a case-based approach to discuss new and existing diagnostic approaches, options for on-demand medications, and individualized strategies for long-term management.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Clinical Viewpoints Hereditary Angioedema lecture library includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert faculty. The slides will be continuously evaluated and updated for current relevance.

Activity Summary:
Clinical Viewpoints HLH includes a curriculum that highlights the very latest clinical data in Hemophagocytic Lymphohistiocytosis (HLH). Slides are developed and updated throughout the year by leading HLH expert physicians. The Lecture Library offers various topics that can be accessed for AMA or ANCC credit. Review the content and complete the pre- and post-tests and evaluation to receive your credit.

HLH is an aggressive and life-threatening syndrome of excessive immune activation. In persons with HLH, timely diagnosis and appropriate treatment are essential to achieving a successful outcome. This activity will utilize case-based scenarios to review the diverse clinical presentations of suspected HLH, time-efficient approaches for diagnosis, and considerations for targeted treatment and supportive management strategies. Continue to visit the Lecture Library series throughout 2022 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints HLH Planning Committee.

Activity Summary:
The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to continual updates from ongoing clinical trials on recently approved and emerging treatment approaches. Clinicians therefore need to stay abreast with recent progress to enable improved outcomes for patients.

This educational Clinical Clip will highlight important advances in RRMM based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting

Activity Summary:
The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies.

This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Activity Summary:
Clinicians need to keep up with recent progress in low-risk myelodysplastic syndromes (MDS) to facilitate appropriate integration of newly approved and novel therapies

This educational Clinical Clip will highlight key updates in low-risk MDS based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Activity Summary:
Until recently, there has been a lack of treatment options for high-risk MDS. An increased understanding of the genetics and signaling pathways has led to the development of several novel agents and combinations for the treatment of high-risk MDS.

In this activity, Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji will deliberate on the most promising emerging therapies and their potential in improving outcomes for patients with high-risk MDS.

Activity Summary:
High-risk myelodysplastic syndromes (MDS) pose a challenge in terms of diagnosis, risk stratification, and treatment. Additionally, in recent years, the clinical, molecular, cellular, and immunological factors associated with high-risk MDS have become clearer.

This has led to several updates in the diagnosis and management of high-risk MDS, which will be discussed by Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji. The expert faculty will also review clinical case scenarios to guide participants in integrating recent updates in high-risk MDS.

Activity Summary:

These certified AMA/ANCC/ACPE activities feature a discussion among three experts that will review the current and emerging treatment landscape of high-risk myelodysplastic syndromes (MDS). The program includes two activities that will feature the faculty discussing recent updates in the standard of care for high-risk MDS and what is on the horizon for high-risk MDS.

Activity Summary:
Pulmonary hypertension due to interstitial lung disease (PH-ILD) is a debilitating condition that has been classified recently. It poses significant challenges for clinical practice in terms of diagnosis and treatment. Updates in the understanding and management of PH-ILD, are hence widely anticipated.

These educational Clinical Clips will highlight important advances in the medical management of patients with PH-ILD on data presented at the American College of Chest Physicians Annual Meeting 2021.

Activity Summary:
Effective strategies for immune thrombocytopenia (ITP) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with ITP based on data presented at the 2021 International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress.

Activity Summary:
Effective strategies for immune thrombocytopenia (ITP) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with ITP based on data presented at the 2021 European Hematology Association (EHA) Virtual Congress.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease. Slides are developed and updated throughout the year by leading pulmonology expert physicians. Continue to visit the Lecture Library series throughout 2021 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

This activity is comprised of two clinical case scenarios to illustrate best-practice recommendations for diagnosis and further treatment and management of patients presenting with PH-ILD. The slides will provide guidance on safely and effectively integrating recent updates and evidence in PH-ILD into clinical practice.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
This certified CME/CNE activity features a recorded discussion among three experts reviewing new therapies and protocols to improve outcomes in (Graft Versus Host Disease) GVHD.

This educational activity will focus on the new therapies and protocols to improve outcomes in GVHD. Data will be reviewed and analyzed by expert faculty while discussing common patient scenarios and best practices in treatment.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease. Slides are developed and updated throughout the year by leading pulmonology expert physicians. Continue to visit the Lecture Library series throughout 2021 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

This activity is designed to provide an overview of the diagnosis, treatment, and management of patients presenting with PH-ILD. Latest evidence from completed and ongoing clinical trials will be presented to identify therapeutic approaches useful in reducing the symptom burden of afflicted patients. Current treatment paradigms, their limitations, and new developments in PH-ILD will also be discussed.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease. Slides are developed and updated throughout the year by leading PH-ILD expert physicians. The Lecture Library offers various topics that can be accessed for AMA, ANCC or ACPE credit. Select your topic of interest and complete the pre/posttest and evaluation.

Continue to visit the Lecture Library series throughout 2021 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

Activity Summary:
The Clinical Viewpoints Hereditary Angioedema lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slides developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

The field of hereditary angioedema (HAE) has recently evolved with the advent of new and forthcoming diagnostic and treatment measures. In particular, the shift toward oral medications will most certainly improve the quality of life for HAE patients. This lecture provides an overview of current diagnostic and treatment procedures recommended by the World Allergy Organization (WAO) and the United States Hereditary Angioedema Association Medical Advisory Board (US HAEA MAB) and summarizes forthcoming new advances in the field of HAE.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:

This certified CME/CNE activity features a recorded discussion among three experts that reviews the latest research and options for the management of patients with MPNs.

This activity will feature Dr. Srdan Verstovsek, Dr. Ruben Mesa and Dr. John Mascarenhas discussing the standard of care for Polycythemia Vera and Myelofibrosis. The discussion will be supplemented by slides based on key discussion points which are available for download.

Activity Summary:
Treatment choices for chronic immune thrombocytopenia (ITP) are complicated by the heterogeneity of the disease and the inability not only to diagnose it but also to objectively predict patient responses to treatment and outcomes. With lack of head-to-head clinical trial comparisons to guide therapeutic options and sequencing of treatment strategies, as well as the development of emerging agents, expert opinion is critical in guiding clinical decision-making. Furthermore, ITP in the elderly and pregnant patient poses considerable challenges, so specific individualized management strategies ideally should be considered to optimize outcomes.

Using patient case studies, James Bussel, MD and Hanny Al-Samkari, MD discuss real-life management of patients with chronic ITP.